Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights. “Over the past year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results